دورية أكاديمية
أعرض في EDS

Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.

التفاصيل البيبلوغرافية
العنوان: Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity.
المؤلفون: Bol KF; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands., Aarntzen EH; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands.; Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands., Pots JM; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., Olde Nordkamp MA; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., van de Rakt MW; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., Scharenborg NM; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., de Boer AJ; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., van Oorschot TG; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., Croockewit SA; Department of Hematology, Radboud University Medical Centre, Nijmegen, The Netherlands., Blokx WA; Department of Pathology, Radboud University Medical Centre, Nijmegen, The Netherlands., Oyen WJ; Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands., Boerman OC; Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands., Mus RD; Department of Radiology and Nuclear Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands., van Rossum MM; Department of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands., van der Graaf CA; Department of Pulmonary Diseases, Radboud University Medical Centre, Nijmegen, The Netherlands., Punt CJ; Department of Medical Oncology, Academic Medical Centre, Amsterdam, The Netherlands., Adema GJ; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., Figdor CG; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands., de Vries IJ; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, The Netherlands., Schreibelt G; Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Centre, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. Gerty.Schreibelt@radboudumc.nl.
المصدر: Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2016 Mar; Vol. 65 (3), pp. 327-39. Date of Electronic Publication: 2016 Feb 10.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 8605732 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0851 (Electronic) Linking ISSN: 03407004 NLM ISO Abbreviation: Cancer Immunol Immunother Subsets: MEDLINE
أسماء مطبوعة: Publication: Berlin : Springer Verlag
Original Publication: Berlin ; New York, NY : Springer International, c1982-
مواضيع طبية MeSH: Cancer Vaccines/*immunology , Dendritic Cells/*immunology , Melanoma/*therapy , Monocytes/*cytology, Adult ; Aged ; BCG Vaccine/immunology ; Cancer Vaccines/adverse effects ; Dinoprostone/pharmacology ; Female ; Hemocyanins/immunology ; Humans ; Male ; Melanoma/immunology ; Middle Aged ; Monophenol Monooxygenase/genetics ; Monophenol Monooxygenase/immunology ; T-Lymphocytes/immunology ; Vaccination ; gp100 Melanoma Antigen/genetics ; gp100 Melanoma Antigen/immunology
مستخلص: Dendritic cell (DC)-based immunotherapy is explored worldwide in cancer patients, predominantly with DC matured with pro-inflammatory cytokines and prostaglandin E2. We studied the safety and efficacy of vaccination with monocyte-derived DC matured with a cocktail of prophylactic vaccines that contain clinical-grade Toll-like receptor ligands (BCG, Typhim, Act-HIB) and prostaglandin E2 (VAC-DC). Stage III and IV melanoma patients were vaccinated via intranodal injection (12 patients) or combined intradermal/intravenous injection (16 patients) with VAC-DC loaded with keyhole limpet hemocyanin (KLH) and mRNA encoding tumor antigens gp100 and tyrosinase. Tumor antigen-specific T cell responses were monitored in blood and skin-test infiltrating-lymphocyte cultures. Almost all patients mounted prophylactic vaccine- or KLH-specific immune responses. Both after intranodal injection and after intradermal/intravenous injection, tumor antigen-specific immune responses were detected, which coincide with longer overall survival in stage IV melanoma patients. VAC-DC induce local and systemic CTC grade 2 and 3 toxicity, which is most likely caused by BCG in the maturation cocktail. The side effects were self-limiting or resolved upon a short period of systemic steroid therapy. We conclude that VAC-DC can induce functional tumor-specific responses. Unfortunately, toxicity observed after vaccination precludes the general application of VAC-DC, since in DC maturated with prophylactic vaccines BCG appears to be essential in the maturation cocktail.
References: Cancer Immunol Immunother. 2011 Feb;60(2):249-60. (PMID: 21069321)
PLoS One. 2014;9(11):e113472. (PMID: 25409184)
Clin Cancer Res. 2013 Mar 15;19(6):1525-33. (PMID: 23382117)
Nat Med. 2004 May;10(5):475-80. (PMID: 15122249)
Cancer Res. 2013 Jan 1;73(1):19-29. (PMID: 23087058)
Crit Rev Oncol Hematol. 2008 May;66(2):118-34. (PMID: 18262431)
Cancer Immunol Immunother. 2012 Nov;61(11):2003-11. (PMID: 22527252)
Ann Oncol. 2006 Apr;17(4):563-70. (PMID: 16418308)
J Immunol Methods. 2005 Mar;298(1-2):61-72. (PMID: 15847797)
J Clin Oncol. 2015 Mar 1;33(7):773-81. (PMID: 25605840)
Anticancer Res. 2010 Dec;30(12):5091-7. (PMID: 21187495)
Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5256-61. (PMID: 17875753)
J Clin Oncol. 2005 Aug 20;23(24):5779-87. (PMID: 16110035)
Eur Urol. 1989;16(3):161-4. (PMID: 2744050)
Oncoimmunology. 2015 Jun 5;5(1):e1057673. (PMID: 26942068)
Cancer Res. 2012 Dec 1;72(23):6102-10. (PMID: 23010076)
J Immunol Methods. 2012 Mar 30;377(1-2):23-36. (PMID: 22269772)
Int J Cancer. 2001 Jul 15;93(2):243-51. (PMID: 11410873)
Cancer Immunol Immunother. 2009 Jan;58(1):145-51. (PMID: 18392619)
Oncoimmunology. 2015 Apr 1;4(8):e1019197. (PMID: 26405571)
J Immunol. 2012 Jan 1;188(1):21-8. (PMID: 22187483)
Nat Biotechnol. 2005 Nov;23(11):1407-13. (PMID: 16258544)
Lancet. 1999 Jan 30;353(9150):345-50. (PMID: 9950438)
J Immunother. 2011 Jun;34(5):448-56. (PMID: 21577140)
Cancer Res. 2003 Jan 1;63(1):12-7. (PMID: 12517769)
Nat Rev Immunol. 2004 Jul;4(7):499-511. (PMID: 15229469)
Nature. 1998 Mar 19;392(6673):245-52. (PMID: 9521319)
Nat Immunol. 2004 Oct;5(10):987-95. (PMID: 15454922)
Blood. 2010 Jul 29;116(4):564-74. (PMID: 20424184)
Clin Cancer Res. 2011 Sep 1;17(17):5725-35. (PMID: 21771874)
Nat Immunol. 2005 Feb;6(2):163-70. (PMID: 15654341)
Clin Cancer Res. 2012 Oct 1;18(19):5460-70. (PMID: 22896657)
Clin Cancer Res. 2003 Nov 1;9(14):5091-100. (PMID: 14613986)
J Clin Oncol. 2011 Jan 20;29(3):330-6. (PMID: 21149657)
Nat Med. 1998 Mar;4(3):328-32. (PMID: 9500607)
فهرسة مساهمة: Keywords: Dendritic cells; Immunotherapy; Maturation; Melanoma; Prophylactic vaccines; Toll-like receptor ligands
المشرفين على المادة: 0 (BCG Vaccine)
0 (Cancer Vaccines)
0 (gp100 Melanoma Antigen)
9013-72-3 (Hemocyanins)
EC 1.14.18.1 (Monophenol Monooxygenase)
FV4Y0JO2CX (keyhole-limpet hemocyanin)
K7Q1JQR04M (Dinoprostone)
تواريخ الأحداث: Date Created: 20160211 Date Completed: 20160729 Latest Revision: 20201226
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC4779136
DOI: 10.1007/s00262-016-1796-7
PMID: 26861670
قاعدة البيانات: MEDLINE
الوصف
تدمد:1432-0851
DOI:10.1007/s00262-016-1796-7